Celltrion’s Kim Emphasizes Innovation As Pipeline Grows
But Company Sees US Biosimilar Interchangeability Designation As ‘Unnecessary’
Executive Summary
Celltrion will adopt a “next generation” innovative approach to developing biosimilars as it continues to bolster its pipeline, HoUng Kim, head of Celltrion Healthcare’s medical and marketing division, tells Generics Bulletin in an exclusive interview. But the firm sees the US interchangeability designation as an “unnecessary” regulatory barrier.